

Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism

Johannes Bitzer

Cosignatories

Jean-Jacques Amy,¹ Rob Beerthuisen,² Martin Birkhäuser,³ Teresa Bombas,⁴ Mitchell Creinin,⁵ Philip D Darney,⁶ Lisa Ferreira Vicente,⁷ Kristina Gemzell-Danielsson,⁸ Bruno Imthurn,⁹ Jeffrey T Jensen,¹⁰ Andrew M Kaunitz,¹¹ Ali Kubba,¹² Medard M Lech,¹³ Diana Mansour,¹⁴ Gabriele Merki,¹⁵ Thomas Rabe,¹⁶ Katarina Sedlecki,¹⁷ David Serfaty,¹⁸ Jacques Seydoux,¹⁹ Lee P Shulman,²⁰ Regine Sitruk-Ware,²¹ Sven O Skouby,²² Anne Szarewski,²³ James Trussell,²⁴ Carolyn Westhoff²⁵

For numbered affiliations see end of article.

Correspondence to

Professor Dr Johannes Bitzer, Chief Physician and Chairman Department of Obstetrics and Gynaecology, University Hospital Basel, Basel, Switzerland; Johannes.Bitzer@usb.ch

Received 15 March 2013
Accepted 18 March 2013
Published Online First
12 April 2013

A NEW PILL SCARE? HOW DID IT COME ABOUT AND HOW SHOULD WE TACKLE IT?

The controversy around the combined hormonal contraceptives (CHCs) of the so-called third (containing gestodene or desogestrel) and fourth generation (containing drospirenone, DRSP) has reached a highly emotional political dimension in which all those who are professionally responsible for women's health are involved: the national health authorities, the pharmaceutical companies, the professional organisations, the prescribers, the media and the public (i.e. the current or potential users of CHCs).

The – initially scientific – controversy has now led to a public health dispute that culminated in the decision of the French authorities to withdraw the combination containing ethinylestradiol (EE) and cyproterone acetate (CPA) from the market. The potential impact of this measure, namely the loss of confidence in *all* CHCs, could be quite serious.

WHAT TRIGGERED THIS CRISIS?

Several registry-based studies published in the *British Medical Journal*, particularly

the one based on the Danish Registry, indicated that there is an increased risk of venous thromboembolism (VTE) associated with the intake of third- and fourth-generation combined oral contraceptives (COCs) compared to preparations containing the progestogen levonorgestrel (LNG).^{1–5} The relative risk (RR) was around 2, and the absolute attributable risk was estimated to be (dependent on the background prevalence rate) between 2 to 8 per 10 000 users per year.⁶

A very recent systematic review and meta-analysis of the possible link between treatment with CHCs and VTE concluded that, in this regard, (1) CHCs containing LNG or norgestimate were the safest, (2) those containing desogestrel, DRSP or CPA were associated with a significantly higher risk than CHCs containing LNG, and (3) the augmented risk of VTE found for pills containing gestodene compared to COCs with LNG appeared to be smaller than in earlier studies.⁷

These results contrast with those of published prospective cohort studies, sponsored by Bayer HealthCare, at the request of the European Medicine

To cite: Bitzer J, Amy J-J, Beerthuisen R, et al. *J Fam Plann Reprod Health Care* 2013;**39**:156–159.

Agency (EMA) and the Food and Drug Administration (FDA) for an expanded post-marketing surveillance, which did not find such differences. This discrepancy led to an intensive scientific discussion among epidemiologists about possible confounders and biases in the published studies.^{8,9}

The authorities at that time informed women about the controversial results and the possible – but not definitively proven – increased risk of the newer preparations. They encouraged healthcare professionals to balance risks and benefits of the different preparations in a process of shared decision-making with the individual woman, and advised women to continue treatment with the currently used contraceptive to avoid the previously observed rise in the number of abortions following the ‘pill scare’ in 1995.^{10,11}

The unresolved scientific debate continued thereafter and was given new impulse by different publications. One publication reported an increased risk of VTE in users of COCs containing DRSP and CPA.¹² Another one based on the Danish Registry indicated that treatment with the transdermal patch and the vaginal ring was also linked to a greater risk of VTE, whereas the LNG-releasing-intrauterine system (LNG-IUS) did not increase or even decreased that risk compared to non-users. In this publication the authors gave practical advice about how to switch from the aforementioned contraceptives to either a LNG-containing pill, a LNG-IUS or a non-hormonal method.^{13,14} Again, these results are in direct contrast to those of another cohort study conducted in the USA, which did not show a difference in VTE risk between the vaginal ring and COCs.¹⁵

These publications warning about the increased risk of third- and fourth-generation contraceptives and CPA-containing pills were received with great interest by the media. Dramatic individual cases of VTE in women using a newer COC or a pill combining EE and CPA were changing the scientific controversy into a highly emotional debate in which the original discussion about epidemiological methods and statistics turned into a fight between ‘ideologies’.^{16–20}

On one side are the pharmaceutical industry, epidemiologists, physicians who work with the pharmaceutical industry, scientific societies and practitioners who see the usefulness of these new contraceptive methods and want them to remain available for women. On the other side are the epidemiologists, practitioners, journalists and lawyers who feel that they must keep women from resorting to using these newer methods, which they consider to be associated with a greater risk to health.

The first group is accused by the second one of acting out of a commercial interest. The second group is blamed by the first one for seeking restrictions and a change of practice based at best on debatable evidence and at worst on biased reporting, thus creating

fears that may lead to another pill scare with the consequences that were seen previously. All of this has created a climate in which critical and considered thinking has become very difficult, and which has put so much pressure on the authorities that the latter feel compelled to act, as has happened in France recently. This crisis is to the disadvantage of all, but especially to women.

Epidemiological data – and, in particular, registry data – cannot stand alone. Only when these data are combined with the outcome of solid clinical trials is there a platform for establishing valid clinical guidelines.

OUR PLEA: LET US COME BACK TO OUR SHARED OBJECTIVES²¹

1 It can be taken for granted that all parties involved in this ‘confrontation’ share the same objective, namely to achieve the best for women’s health and to put at their disposal effective and well-tolerated contraceptives.

2 Everybody concurs that contraceptive methods are needed that possess the greatest possible efficacy, safety and tolerability and, if possible, additional health benefits. All these elements should be integrated in the individual risk/benefit evaluation.

3 Everyone is probably in agreement that no method currently available or likely to be developed at a later date will be 100% effective, risk-free, well tolerated by all users, and associated with non-contraceptive benefits justifying and facilitating its long-term use.

4 In view of this fact, everyone is likely to acknowledge that a large spectrum of methods should be available in order to tailor contraceptive choice to individual women’s needs.

5 Everyone concerned undoubtedly also concedes that each contraceptive decision must be properly balanced and based on the best evidence on record about risks and benefits. This information should be delivered in a way that helps women to understand the scientific evidence and takes into account women’s needs and values so that, after having been fully informed, they are able to individually weigh up the relative importance of this evidence. By educating and counselling women in this way, they will be appropriately informed in respect of the decision-making process.²²

WHAT ARE THE CONCLUSIONS BASED ON THESE OBJECTIVES?

All parties involved must be interested in conducting well-designed prospective studies addressing the relevant outcomes of the use of contraceptive methods (efficacy, safety, side effects, non-contraceptive benefits, and so on). This will require the collaboration of health authorities, industry, epidemiologists, physicians and women’s organisations.

At the present time, data are lacking or are controversial. As a result, healthcare professionals are left with a degree of uncertainty that they will inevitably end up sharing with their patients. It is important that patients receive balanced information from their healthcare providers, which then helps them to choose the contraceptive method that best fits their individual needs and their risk profile.^{21,22}

SUMMARY OF THE CURRENT EVIDENCE CONCERNING THE RISK OF VTE

Several registry-based case-control studies have come to the conclusion that the use of third- and fourth-generation CHCs is associated with a higher risk (RR 1.6–2.4) of VTE than that related to the use of CHCs containing LNG. Two large cohort studies did not find such a difference.

Many factors contribute to VTE risk (e.g. age, duration of use, weight, family history, etc.), which makes epidemiological studies vulnerable to bias and confounders, and may explain contradictory results.²¹ Additional prospective well-controlled studies are needed.

The inherent inability of database studies to adequately control for baseline confounders render this design less suitable for providing further clarification.

Some epidemiologists question whether the RR increase of around 2 described in the aforementioned case-control studies reflects a clinically relevant difference.

Several studies have shown that the risk of VTE during pregnancy and the postpartum period is considerably higher (29–300 per 10 000 users) than during use of a CHC.²¹

PRACTICAL RECOMMENDATIONS

In order to reduce the VTE risk it is most important to avoid prescribing CHCs to women at elevated risk for VTE. The World Health Organization *Medical Eligibility Criteria for Contraceptive Use*²³ should serve as a first point of guidance for prescribers.

Women who have a higher risk of VTE due to obesity, smoking, family history of VTE or cardiovascular disease should undergo a personal risk assessment and be advised appropriately.

The hormonal contraceptive methods with the lowest VTE risk are progestogen-only contraceptives. While there is some evidence from registry studies that CHCs containing LNG are associated with less risk than those containing third- and fourth-generation progestogens, large, well-designed cohort studies have not confirmed this difference in risk, and the controversy is not yet resolved.²⁴ Even if third- and fourth-generation pills are associated with a higher RR, the absolute difference in risk is small, and is estimated by some authors to be of the order of 4–6 attributable cases per 10 000 users per year.^{20,24}

The risk of death from VTE is low. Based on a RR of 2, the excess risk of death for a woman taking modern pills is 1 in 100 000, which is much lower than the risk of everyday activities such as cycling.²²

In the decision-making process regarding the choice of a contraceptive method by the individual patient, VTE risk is but one element in the equation. Other elements are efficacy, tolerability, additional health benefits, and whether or not the patient can/will use an alternative method. These factors must be taken into account and discussed with the individual patient. Results from long-term cohort studies on the positive impact of the use of hormonal contraceptives on global health parameters of women should be part of the information given to women.^{25–27}

Both epidemiological data and clinical trials must be taken into account when best practice is defined. Regulatory restrictions of previously registered methods should only be made after careful assessment of all the available evidence.

Cosignatory geographical locations

- ¹Jean-Jacques Amy, Brussels, Belgium
- ²Rob Beerhuizen, Winterswijk, The Netherlands
- ³Martin Birkhäuser, Basel, Switzerland
- ⁴Teresa Bombas, Coimbra, Portugal
- ⁵Mitchell Creinin, Sacramento, CA, USA
- ⁶Philip D Darney, San Francisco, CA, USA
- ⁷Lisa Ferreira Vicente, Lisbon, Portugal
- ⁸Kristina Gemzell-Danielsson, Stockholm, Sweden
- ⁹Bruno Imthurn, Zurich, Switzerland
- ¹⁰Jeffrey T Jensen, Portland, OR, USA
- ¹¹Andrew M Kaunitz, Jacksonville, FL, USA
- ¹²Ali Kubba, London, UK
- ¹³Medard M Lech, Warsaw, Poland
- ¹⁴Diana Mansour, Newcastle upon Tyne, UK
- ¹⁵Gabriele Merki, Zurich, Switzerland
- ¹⁶Thomas Rabe, Heidelberg, Germany
- ¹⁷Katarina Sedlecki, Belgrade, Serbia
- ¹⁸David Serfaty, Paris, France
- ¹⁹Jacques Seydoux, Delémont, Switzerland
- ²⁰Lee P Shulmann, Chicago, IL, USA
- ²¹Regine Sitruk-Ware, New York, NY, USA
- ²²Sven O Skouby, Copenhagen, Denmark
- ²³Anne Szarewski, London, UK
- ²⁴James Trussell, Princeton, NY, USA
- ²⁵Carolyn Westhoff, New York, NY, USA

Competing interests The authors presently consult and in the past have consulted with manufacturers of hormonal products used in reproductive medicine. A detailed conflict of interest declaration for each cosignatory is available online as a data supplement at <http://jfprhc.bmj.com/lookup/suppl/doi:10.1136/jfprhc-2013-100624/-/DC1>

Provenance and peer review This statement has not been subjected to the journal's usual peer review process.

Joint publication This statement is also published simultaneously in the June 2013 issue of the *European Journal of Contraception and Reproductive Health Care* [doi:10.3109/13625187.2013.792637].

REFERENCES

- 1 Lidegaard Ø, Løkkegaard E, Svendsen AL, *et al.* Hormonal contraception and risk of venous thromboembolism: national follow-up study. *BMJ* 2009;339:b2890.
- 2 van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, *et al.* The venous thrombotic risk of oral contraceptives, effects of estrogen dose and progestagen type: results of the MEGA case-control study. *BMJ* 2009;339:b2921.
- 3 Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. *BMJ* 2011;340:d2151.
- 4 Parkin L, Sharples K, Hernandez RK, *et al.* Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. *BMJ* 2011;340:d2139.
- 5 Lidegaard Ø Nielsen LH, Skovlund CW, *et al.* Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. *BMJ* 2011;343:d6423.
- 6 Heinemann LAJ, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. *Contraception* 2007;75:328–336.
- 7 Martínez F, Ramírez I, Pérez-Campos E, *et al.* Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. *Eur J Contracept Reprod Health Care* 2012;17:7–29.
- 8 Dinger JC, Heinemann LAJ, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on Oral Contraceptives based on 142,475 women-years of observation. *Contraception* 2007;75:344–354.
- 9 Seeger JD, Loughlin J, Eng PM, *et al.* Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. *Obstet Gynecol* 2007;110:587–593.
- 10 Skjeldestad FE. Increased number of induced abortions in Norway after media coverage of adverse vascular events from the use of third-generation oral contraceptives. *Contraception* 1997;55:11–14.
- 11 Goodyear-Smith A, Arroll B. Termination of pregnancy following panic-stopping of oral contraceptives. *Contraception* 2002;66:163–167.
- 12 Van Vliet HAA, Winkel TA, Noort I, *et al.* Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. *J Thromb Haemost* 2004;2:2060–2062.
- 13 Lidegaard Ø Nielsen LH, Skovlund CW, *et al.* Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. *BMJ* 2012;344:e2990.
- 14 Lidegaard Ø Milsom I, Geirsson RT, *et al.* Hormonal contraception and venous thromboembolism *Acta Obstet Gynecol Scand* 2012;91:769–778.
- 15 Dinger J, Pineda AA. Risk of VTE in users of an etonogestrel-containing vaginal ring combined oral contraceptives. Paper presented at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG), San Diego, CA, USA, 7 May 2012.
- 16 Spitzer WO. The aftermath of a pill scare: regression to reassurance. *Hum Reprod Update* 1999;5:736–745.
- 17 Lewis MA, MacRae KD, Kuhl-Habich D, *et al.* The differential risk of oral contraceptives: the impact of full exposure history. *Hum Reprod* 1999;14:1493–1499.
- 18 Dinger J. Oral contraceptives and venous thromboembolism: old questions revisited. *J Fam Plann Reprod Health Care* 2009;35:211–213.
- 19 Shapiro S, Dinger J. Risk of venous thromboembolism among users of oral contraceptives: a review of two recently published studies. *J Fam Plann Reprod Health Care* 2010; 36:33–38.
- 20 Heinemann K, Heinemann LA. Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel. *J Fam Plann Reprod Health Care* 2011;37:132–135.
- 21 Reid RL, Westhoff C, Mansour D, *et al.* Oral contraceptives and venous thromboembolism – Consensus opinion from an international workshop held in Berlin, Germany in December 2009. *J Fam Plann Reprod Health Care* 2010;36:117–122.
- 22 Jensen JT, Trussell J. Communicating risk: does scientific debate compromise safety. *Contraception* 2012;86:327–329.
- 23 World Health Organization. *Medical Eligibility for Contraceptive Use* (4th edn). 2010. http://www.who.int/reproductivehealth/publications/family_planning/9789241563888/en/index.html [accessed 6 March 2013].
- 24 Dinger J, Shapiro S. Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. *J Fam Plann Reprod Health Care* 2012;38:2–6.
- 25 Hannaford PC, Iversen L. Mortality among oral contraceptive users: an evolving story. *Eur J Contracept Reprod Health Care* 2013;18:1–4.
- 26 Hannaford PC, Iversen L, MacFarlane TV, *et al.* Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. *BMJ* 2010;340:c927.
- 27 Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. *Contraception* 2010;82:221–229.

Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism

Cosignatories' Affiliations and Conflict of Interest (COI) Declarations

Name/Affiliation	COI Declaration
Johannes Bitzer Department of Obstetrics and Gynaecology, University Hospital Basel, Basel, Switzerland	Recipient of grants and honoraria for research projects, educational lectures and consultant service from Bayer Health Care, Merck (MSD), Gedeon Richter, Pfizer.
Jean-Jacques Amy <i>European Journal of Contraception and Reproductive Health Care</i> , Brussels, Belgium	Read a paper at a meeting organised by MSD; the fee has been donated to a non-governmental organisation.
Rob J C M Beerthuizen Dutch Foundation for Contraception	Recipient of grants and honoraria for research projects, educational lectures and consultant service from Bayer Health Care, Merck (MSD), Pantarhei Bioscience, Prosan International.
Martin Birkhäuser Department of Obstetrics and Gynaecology, University Women's Hospital Bern, Basel, Switzerland	Member of advisory boards of and/or has received honoraria for lectures from AMGEN, MSD, Daiiji Sankyo, Bayer Schering, Abbott, Novartis.
Teresa Bombas Obstetric Service, Centro Hospitalar da Universidade de Coimbra, Coimbra, Portugal	Recipient of grants and honoraria for research projects, educational lectures and consultant service from Bayer Health Care, Merck Sharp and Dohme (MSD) and AffinitésSanté.
Mitchell Creinin Department of Obstetrics and Gynecology, University of California, Davis Health System, Sacramento, CA, USA	Consultant for Merck, Danco and received research support from Medicines360.
Philip D Darney Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, CA, USA	Consultant for Merck, Cermed and Medicines360 and received research support from Medicines360.
Lisa Ferreira Vicente Child and Maternal Health Department, Directorate-General of Health, Portugal	Recipient of grants and honoraria for research projects, educational lectures from Organon, Wyeth Lederle Portugal, Schering-Plough, Bayer Health Care, Merck (MSD), BIAL.

Name/Affiliation	COI Declaration
<p>Kristina Gemzell-Danielsson Division of Obstetrics and Gynecology, Department of Women's and Children's Health, Karolinska Institutet, University Hospital, Stockholm, Sweden</p>	<p>Recipient of grants and honoraria for research projects, educational lectures and consultant services from Bayer Health Care, Merck (MSD), Gedeon Richter, HRA-Pharma.</p>
<p>Bruno Imthurn Klinik Gyn Endokrinologie und Reproduktionsmedizin, Universitätsspital Zürich, Zurich, Switzerland</p>	<p>No conflicts of interest to declare.</p>
<p>Jeffrey T Jensen Department of Obstetrics and Gynecology, Oregon Health and Science University, Portland, OR, USA</p>	<p>Consultant and serves on advisory boards for Bayer Healthcare, HRA Pharma, Merck and the Population Council. Speaker for Bayer Healthcare. Recipient of research support from Abbott Pharmaceuticals, Bayer Healthcare, M-360, the Population Council, Agile Pharmaceuticals and the National Institutes of Health.</p>
<p>Andrew M Kaunitz Department of Obstetrics and Gynecology, University of Florida College of Medicine, Jacksonville, FL, USA</p>	<p>Recipient of grants, consulting fees, honoraria and meeting support from Johnson & Johnson (New Brunswick, NJ, USA), Bayer (Leverkusen, Germany), Merck (Whitehouse Station, NJ, USA) and Teva (Petach Tikva, Israel).</p>
<p>Ali Kubba Department of Obstetrics and Gynaecology, Guy's and St Thomas' NHS Foundation Trust, London, UK</p>	<p>Recipient of grants and honoraria for research projects, educational lectures and consultant services from Bayer Health Care, Merck (MSD) and Gedeon Richter.</p>
<p>Medard M Lech Fertility & Sterility Research Centre, Warsaw, Poland</p>	<p>Recipient of scholarly grants from Gedeon Richter.</p>
<p>Diana Mansour NHS Newcastle and North Tyneside, Community Health, New Croft Centre, Newcastle upon Tyne, UK</p>	<p>Recipient of research grants and honoraria for attending advisory board meetings, developing and delivering educational presentations from Astellas, Bayer plc, Consilient Healthcare, HRA Pharma and MSD.</p>
<p>Gabriele Merki Klinik für Gyn Endokrinologie und Reproduktionsmedizin, Universitätsspital Zürich, Zurich, Switzerland</p>	<p>Financial relationships (lecturer, member of advisory boards and/or consultant) with Bayer-Schering Pharma, Merck Sharp and Dohme and Amgen AG in last 5 years.</p>

Name/Affiliation	COI Declaration
<p>Thomas Rabe Department of Gynaecological Endocrinology and Reproductive Medicine, University Women's Hospital, Medical School Heidelberg, Germany</p>	<p>Recipient of honoraria and travel expenses from Bayer AG, HRA Pharma, MSD and Teva for national and international lectures, advisory boards and consultancy.</p>
<p>Katarina Sedlecki Institute for Mother and Child Health Care of Serbia, Republic Family Planning Centre, Serbia</p>	<p>Recipient of honoraria for giving lectures for various pharmaceutical companies: GlaxoSmithKline, MSD Ltd, Bayer HealthCare and Gedeon Richter.</p>
<p>David Serfaty Président de la Société Francophone de Contraception, Paris, France</p>	<p>Recipient of grants and honoraria for research projects, educational lectures and consultant service from HRA, Conceptus, Gedeon Richter, Bayer.</p>
<p>Jacques Seydoux Président de la Société Suisse de Gynécologie, Delémont, Switzerland</p>	<p>No conflicts of interest to declare.</p>
<p>Lee P Shulman Feinberg School of Medicine of Northwestern University Chicago, Chicago, IL, USA</p>	<p>Recipient of grants and honoraria for research projects, educational lectures and consulting services from Bayer Health Care, Teva, Merck (MSD), Theramex, Watson and Besins.</p>
<p>Regine Sitruk-Ware Rockefeller University and The Population Council, New York, NY, USA</p>	<p>Member of an Advisory Board for Bayer and for Merck, and lectured for Teva.</p>
<p>Sven O Skouby Department of Obstetrics/Gynaecology, Herlev Hospital, Herlev Ringvej, Denmark, Faculty of Health Sciences, University of Copenhagen, and Department of Thrombosis Research, Esbjerg, University of Southern Denmark, Denmark</p>	<p>Consultant for manufacturers of hormonal products including contraceptives and postmenopausal therapies.</p>
<p>Anne Szarewski Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary, University of London, London, UK</p>	<p>Recipient of honoraria, conference sponsorship and consultancy fees from various pharmaceutical companies including Bayer HealthCare Pharmaceuticals and MSD.</p>
<p>James Trussell Office of Population Research, Wallace Hall, Princeton University, Princeton, NJ, USA</p>	<p>Member of Merck's Global Advisory Board and consultant on health economics projects for Bayer.</p>
<p>Carolyn Westhoff Department of Obstetrics and Gynecology, Columbia University, College of Physicians and Surgeons, Columbia University, New York, NY, USA</p>	<p>Research: National Institutes of Health only (no industry-funded research). Consultant/advisor to Agile Therapeutics. DSMB member for Merck and Bayer Phase 4 studies. Editor of <i>Contraception</i> (Elsevier journal).</p>